Personal information

No personal information available

Activities

Collapse all

Works (10)

Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial

BMC Cancer
2021-12 | Journal article
DOI: 10.1186/s12885-021-08088-w
Part of ISSN: 1471-2407
Source: Self-asserted source
Annabel Meireson

Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNγ-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma

Frontiers in Immunology
2021-09-07 | Journal article
DOI: 10.3389/fimmu.2021.736498
Part of ISSN: 1664-3224
Source: Self-asserted source
Annabel Meireson

Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures

Cancers
2021-05-27 | Journal article
DOI: 10.3390/cancers13112630
Contributors: Annabel Meireson; Simon J. Tavernier; Sofie Van Gassen; Nora Sundahl; Annelies Demeyer; Mathieu Spaas; Vibeke Kruse; Liesbeth Ferdinande; Jo Van Dorpe; Benjamin Hennart et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

IDO Expression in Cancer: Different Compartment, Different Functionality?

Frontiers in Immunology
2020-09-24 | Journal article
DOI: 10.3389/fimmu.2020.531491
Part of ISSN: 1664-3224
Source: Self-asserted source
Annabel Meireson

Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma

International Journal of Radiation Oncology*Biology*Physics
2019-07 | Journal article
DOI: 10.1016/j.ijrobp.2019.03.041
Part of ISSN: 0360-3016
Source: Self-asserted source
Annabel Meireson

Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma

European Urology
2019-05 | Journal article
DOI: 10.1016/j.eururo.2019.01.009
Part of ISSN: 0302-2838
Source: Self-asserted source
Annabel Meireson

Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma

Nature Communications
2018-12 | Journal article
DOI: 10.1038/s41467-018-05047-1
Part of ISSN: 2041-1723
Source: Self-asserted source
Annabel Meireson

Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile

Oncotarget
2018-05-18 | Journal article
DOI: 10.18632/oncotarget.25393
Part of ISSN: 1949-2553
Source: Self-asserted source
Annabel Meireson

Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma

International Journal of Radiation Oncology*Biology*Physics
2018-03 | Journal article
DOI: 10.1016/j.ijrobp.2017.11.029
Part of ISSN: 0360-3016
Source: Self-asserted source
Annabel Meireson

A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response

Journal of Translational Medicine
2017-12 | Journal article
DOI: 10.1186/s12967-017-1251-3
Part of ISSN: 1479-5876
Source: Self-asserted source
Annabel Meireson
How many people are using ORCID?